Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : Bulletin from the annual general meeting in Biovica

08/27/2020 | 11:10am EST

The following resolutions were passed at the annual general meeting of Biovica AB (publ) on 27 August 2020 in Uppsala.

Adoption of the accounts for the financial year 2019/2020 and discharge from liability
The annual general meeting, AGM, resolved to adopt the income statement and balance sheet, as well as the consolidated income statement and consolidated balance sheet for the 2019/2020 financial year. The members of the board of directors and the CEO were discharged from liability for the financial year 2019/2020.

Allocation of profit or loss
The AGM resolved that no dividend shall be paid for the financial year 2019/2020 and that the results of the company shall be carried forward.

Renumeration to the board of directors and auditor
The AGM resolved that renumeration to the members of the board of directors shall be SEK 150,000 and to the chairman of the board SEK 400,000. Renumeration to the auditors shall be paid in accordance with approved invoices.

Election of board members and auditor
Lars Holmqvist, Maria Holmlund, Ulf Jungnelius, Anders Rylander, Jesper Söderqvist and Henrik Osvald were re-elected as board members for the period until the end of the next AGM, and Marie-Louise Fjällskog and Annika Carlsson Berg were newly elected. Lars Holmqvist was re-elected as the chairman of the board.

The audit firm Grant Thornton Sweden AB was re-elected as auditor for the period until the end of the next AGM, with Stéphanie Ljungberg as the principal auditor.

Decision on guidelines for remuneration to senior executives
The AGM resolved on guidelines for remuneration to senior executives, which means, among other things, that variable cash remuneration shall not exceed 40 percent of the fixed salary.

Authorisation to issue new shares
The AGM resolved to authorise the board of directors to, on one or several occasions, during the period up until the next AGM, decide on a new issue of shares, convertibles and warrants, with or without deviation from the shareholders' preferential rights corresponding to a maximum of 20 percent of the total share capital.

Decision on the issue of warrants to employees and the board of directors
The AGM resolved on a warrant program for employees of 220,000 options whose maximum dilution effect is estimated to amount to a maximum of approximately 0.93 percent of the total number of shares.

The AGM resolved on a warrant program for the board of directors of 200,000 options whose maximum dilution effect is estimated to amount to a maximum of approximately 0.85 percent of the total number of shares.

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
01/18BIOVICA INTERNATIONAL : DiviTum®TKa in early treatment resistance trial
AQ
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTum®TK..
AQ
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
AQ
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
AQ
2020BIOVICA INTERNATIONAL : DiviTum®TKa included in new UK breast cancer study
AQ
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTum®TKa r..
AQ
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTum®TKa as an early an..
AQ
2020BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
AQ
2020BIOVICA INTERNATIONAL : DiviTum®TKa Monitoring Capabilities Confirmed in SWOG St..
AQ
2020BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
AQ
More news
Financials
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,60 M -4,60 M
Net cash 2021 134 M 15,9 M 15,9 M
P/E ratio 2021 -29,6x
Yield 2021 -
Capitalization 1 168 M 140 M 139 M
EV / Sales 2021 345x
EV / Sales 2022 24,2x
Nbr of Employees 21
Free-Float 75,2%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Technical analysis trends BIOVICA INTERNATIONAL AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 41,30 SEK
Spread / Highest target 149%
Spread / Average Target 62,2%
Spread / Lowest Target -24,9%
EPS Revisions
Managers and Directors
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors